| Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Eansor Norman David | President-Protein Sciences | Mar 04 | Sale | 198.68 | 1,387 | 275,569 | 0 | Mar 06 04:08 PM | | HIGGINS JOHN L | Director | Feb 12 | Option Exercise | 61.46 | 5,000 | 307,300 | 9,021 | Feb 14 04:13 PM | | HIGGINS JOHN L | Director | Feb 12 | Sale | 205.23 | 5,000 | 1,026,133 | 4,021 | Feb 14 04:13 PM | | Kummeth Charles R. | Chief Executive Officer | Jan 06 | Option Exercise | 67.46 | 10,276 | 693,219 | 140,265 | Jan 08 04:34 PM | | Kummeth Charles R. | Chief Executive Officer | Jan 06 | Sale | 217.28 | 10,276 | 2,232,769 | 129,989 | Jan 08 04:34 PM | | Kummeth Charles R. | Chief Executive Officer | Jan 03 | Option Exercise | 67.46 | 7,999 | 539,613 | 137,988 | Jan 06 04:39 PM | | Kummeth Charles R. | Chief Executive Officer | Jan 03 | Sale | 217.56 | 7,999 | 1,740,240 | 129,989 | Jan 06 04:39 PM | | Kummeth Charles R. | Chief Executive Officer | Jan 02 | Option Exercise | 67.46 | 19,843 | 1,338,609 | 149,832 | Jan 06 04:39 PM | | Kummeth Charles R. | Chief Executive Officer | Jan 02 | Sale | 218.59 | 19,843 | 4,337,541 | 129,989 | Jan 06 04:39 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 24 | Option Exercise | 67.46 | 471 | 31,774 | 130,460 | Dec 27 04:31 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 24 | Sale | 222.18 | 471 | 104,648 | 129,989 | Dec 27 04:31 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 23 | Option Exercise | 67.46 | 659 | 44,456 | 130,648 | Dec 27 04:31 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 23 | Sale | 222.08 | 659 | 146,351 | 129,989 | Dec 27 04:31 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 20 | Option Exercise | 67.46 | 5,767 | 389,042 | 135,756 | Dec 23 04:31 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 20 | Option Exercise | 67.46 | 5,767 | 389,042 | 135,756 | Dec 23 04:32 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 20 | Sale | 222.06 | 5,767 | 1,280,632 | 129,989 | Dec 23 04:32 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 20 | Sale | 222.06 | 5,767 | 1,280,632 | 129,989 | Dec 23 04:31 PM | | Furlow Brenda S. | SVP - General Counsel | Dec 12 | Option Exercise | 94.35 | 8,000 | 754,800 | 10,711 | Dec 17 04:32 PM | | Furlow Brenda S. | SVP - General Counsel | Dec 12 | Sale | 215.60 | 8,000 | 1,724,772 | 2,711 | Dec 17 04:32 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 10 | Option Exercise | 67.46 | 703 | 47,424 | 136,459 | Dec 12 04:35 PM | | Kummeth Charles R. | Chief Executive Officer | Dec 10 | Sale | 222.01 | 703 | 156,073 | 135,756 | Dec 12 04:35 PM | | WIENS HAROLD J | Director | Dec 04 | Option Exercise | 87.83 | 2,000 | 175,660 | 7,221 | Dec 06 04:50 PM | | WIENS HAROLD J | Director | Dec 04 | Sale | 217.85 | 2,000 | 435,693 | 5,221 | Dec 06 04:50 PM | | Kummeth Charles R. | Chief Executive Officer | Nov 29 | Sale | 222.62 | 100 | 22,262 | 135,756 | Dec 02 04:22 PM | | Kummeth Charles R. | Chief Executive Officer | Nov 27 | Option Exercise | 67.46 | 11,772 | 794,139 | 147,628 | Dec 02 04:22 PM | | Kummeth Charles R. | Chief Executive Officer | Nov 27 | Sale | 222.12 | 11,772 | 2,614,814 | 135,856 | Dec 02 04:22 PM | | Nusse Roeland | Director | Nov 25 | Option Exercise | 60.79 | 15,000 | 911,900 | 20,721 | Nov 29 11:35 AM | | Nusse Roeland | Director | Nov 25 | Sale | 219.33 | 8,347 | 1,830,731 | 12,374 | Nov 29 11:35 AM | | Hippel James | Chief Financial Officer | Nov 22 | Option Exercise | 94.35 | 23,651 | 2,231,472 | 32,958 | Nov 25 04:25 PM | | Hippel James | Chief Financial Officer | Nov 22 | Sale | 215.59 | 23,651 | 5,098,901 | 9,307 | Nov 25 04:25 PM | | Hippel James | Chief Financial Officer | Nov 21 | Option Exercise | 94.35 | 11,349 | 1,070,778 | 20,656 | Nov 25 04:25 PM | | Hippel James | Chief Financial Officer | Nov 21 | Sale | 215.36 | 11,349 | 2,444,132 | 9,307 | Nov 25 04:25 PM | | Kummeth Charles R. | Chief Executive Officer | Sep 09 | Buy | 185.00 | 200 | 37,000 | 100 | Sep 11 04:42 PM | | Kummeth Charles R. | Chief Executive Officer | Aug 13 | Option Exercise | 67.46 | 7,410 | 499,879 | 110,877 | Aug 15 04:45 PM | | BAUMGARTNER ROBERT V | Director | Aug 07 | Buy | 191.06 | 500 | 95,530 | 8,726 | Aug 09 04:12 PM | | Kummeth Charles R. | Chief Executive Officer | Jul 10 | Option Exercise | 67.46 | 16,969 | 1,144,729 | 109,145 | Jul 12 04:18 PM | | Kummeth Charles R. | Chief Executive Officer | Jul 10 | Sale | 213.12 | 16,969 | 3,616,428 | 92,176 | Jul 12 04:18 PM | | Kummeth Charles R. | Chief Executive Officer | Jul 09 | Option Exercise | 67.46 | 15,037 | 1,014,396 | 107,213 | Jul 10 04:46 PM | | Kummeth Charles R. | Chief Executive Officer | Jul 09 | Sale | 212.43 | 15,037 | 3,194,340 | 92,176 | Jul 10 04:46 PM | | Kummeth Charles R. | Chief Executive Officer | Jul 08 | Option Exercise | 67.46 | 17,994 | 1,213,875 | 110,170 | Jul 10 04:46 PM | | Kummeth Charles R. | Chief Executive Officer | Jul 08 | Sale | 212.75 | 17,994 | 3,828,184 | 92,176 | Jul 10 04:46 PM | | Eansor Norman David | SVP - Novus Biologicals | Jun 12 | Sale | 215.00 | 3,117 | 670,155 | 0 | Jun 14 04:13 PM | | HIGGINS JOHN L | Director | Jun 04 | Option Exercise | 63.03 | 5,000 | 315,150 | 8,526 | Jun 06 04:30 PM | | HIGGINS JOHN L | Director | Jun 04 | Sale | 203.67 | 5,000 | 1,018,346 | 3,526 | Jun 06 04:30 PM | | Furlow Brenda S. | SVP - General Counsel | May 24 | Option Exercise | 0.00 | 5,400 | 0 | 7,589 | May 29 04:29 PM | | Furlow Brenda S. | SVP - General Counsel | May 24 | Sale | 200.00 | 5,400 | 1,080,000 | 2,189 | May 29 04:29 PM | | Hippel James | Chief Financial Officer | May 01 | Option Exercise | 86.25 | 35,000 | 3,018,750 | 39,382 | May 02 04:14 PM | | Kelderman Kim | President, Diagnostics & Genom | May 01 | Option Exercise | 202.13 | 1,667 | 336,951 | 1,667 | May 02 04:18 PM | | Hippel James | Chief Financial Officer | May 01 | Sale | 203.08 | 35,000 | 7,107,681 | 4,382 | May 02 04:14 PM |
|
